Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients

Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.

Scratching
Itching is a distressing symptom of atopic dermatitis • Source: Shutterstock

Gaining EU approval for the use of the biologic atopic dermatitis therapy Dupixent (dupilumab) in adolescents with moderate-to-severe atopic dermatitis, and positive top-line results in children aged six to 11 years with severe atopic dermatitis, will likely cement the lead currently enjoyed by Sanofi and its collaborator, Regeneron Pharmaceuticals Inc., in developing and marketing a biologic for the condition.

However, there are a plethora of biologics in early and late-stage clinical development for atopic dermatitis, indicating the therapeutic segment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category